BRPI9917739B8 - composto intermediário na preparação de inibidores de cox-2 - Google Patents

composto intermediário na preparação de inibidores de cox-2

Info

Publication number
BRPI9917739B8
BRPI9917739B8 BRPI9917739A BR9917739A BRPI9917739B8 BR PI9917739 B8 BRPI9917739 B8 BR PI9917739B8 BR PI9917739 A BRPI9917739 A BR PI9917739A BR 9917739 A BR9917739 A BR 9917739A BR PI9917739 B8 BRPI9917739 B8 BR PI9917739B8
Authority
BR
Brazil
Prior art keywords
cox
inhibitors
preparation
intermediate compound
useful
Prior art date
Application number
BRPI9917739A
Other languages
English (en)
Other versions
BRPI9917739B1 (pt
Inventor
G Corley Edward
W Davies Ian
Rossen Kai
J Pye Philip
D Larsen Robert
Original Assignee
Merck Sharp & Dohme
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Schering Corp filed Critical Merck Sharp & Dohme
Publication of BRPI9917739B1 publication Critical patent/BRPI9917739B1/pt
Publication of BRPI9917739B8 publication Critical patent/BRPI9917739B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/30—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having nitrogen atoms of imino groups quaternised

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

composto intermediário na preparação de inibidores de cox-2. a invenção abrange um processo para preparar compostos de fórmula (1) úteis no tratamento de doenças mediadas por cicloxigenase-2, incluindo compostos intermediários úteis no referido processo.
BRPI9917739A 1998-04-24 1999-04-20 composto intermediário na preparação de inibidores de cox-2 BRPI9917739B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8288898P 1998-04-24 1998-04-24
US8566898P 1998-05-15 1998-05-15
BRPI9909844-0A BR9909844B1 (pt) 1998-04-24 1999-04-20 processo de preparação de compostos inibidores de cox-2.
PCT/US1999/008645 WO1999055830A2 (en) 1998-04-24 1999-04-20 Process for synthesizing cox-2 inhibitors

Publications (2)

Publication Number Publication Date
BRPI9917739B1 BRPI9917739B1 (pt) 2016-05-03
BRPI9917739B8 true BRPI9917739B8 (pt) 2021-05-25

Family

ID=26767964

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI9909844-0A BR9909844B1 (pt) 1998-04-24 1999-04-20 processo de preparação de compostos inibidores de cox-2.
BRPI9917739A BRPI9917739B8 (pt) 1998-04-24 1999-04-20 composto intermediário na preparação de inibidores de cox-2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI9909844-0A BR9909844B1 (pt) 1998-04-24 1999-04-20 processo de preparação de compostos inibidores de cox-2.

Country Status (27)

Country Link
US (2) US6040319A (pt)
EP (1) EP1071745B1 (pt)
JP (2) JP3325264B2 (pt)
KR (1) KR100414998B1 (pt)
CN (1) CN1178658C (pt)
AR (1) AR015279A1 (pt)
AT (1) ATE272613T1 (pt)
AU (1) AU759469B2 (pt)
BR (2) BR9909844B1 (pt)
CA (1) CA2329193C (pt)
CZ (1) CZ292515B6 (pt)
DE (1) DE69919151T2 (pt)
DK (1) DK1071745T3 (pt)
EA (1) EA002975B1 (pt)
ES (1) ES2226378T3 (pt)
HR (1) HRP20000722B1 (pt)
HU (1) HU227627B1 (pt)
IL (2) IL139127A0 (pt)
NZ (1) NZ507597A (pt)
PL (1) PL193248B1 (pt)
PT (1) PT1071745E (pt)
RS (1) RS49945B (pt)
SI (1) SI1071745T1 (pt)
SK (1) SK284805B6 (pt)
TW (1) TW474934B (pt)
UA (1) UA57143C2 (pt)
WO (1) WO1999055830A2 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
DK1159270T3 (da) * 1999-01-14 2004-02-23 Lonza Ag Fremgangsmåde til fremstilling af 1-(6-methylpyridin-3-yl)-2-[(4-(methylsulfonyl)phenyl]ethanon
KR100446324B1 (ko) 1999-01-14 2004-08-30 론자 아게 1-(6-메틸피리딘-3-일)-2-[4-(메틸술포닐)페닐]에타논 및이의 제조 방법
JP2001115963A (ja) 1999-10-13 2001-04-27 Daikin Ind Ltd 圧縮機
US6858631B1 (en) 1999-11-29 2005-02-22 Merck & Co., Inc. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl
CA2391650C (en) 1999-11-29 2011-01-25 Merck & Co., Inc. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl
CO5261556A1 (es) * 1999-12-08 2003-03-31 Pharmacia Corp Composiciones inhibidoras de ciclooxigenasa-2 que tiene rapido acceso de efecto terapeutico
JP2001261653A (ja) * 2000-03-17 2001-09-26 Sankio Chemical Co Ltd ピリジン誘導体の合成法
US6800647B2 (en) 2000-05-26 2004-10-05 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3]bipyridinyl in pure crystalline form and process for synthesis
US6521642B2 (en) 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
PH12001001175B1 (en) * 2000-05-26 2006-08-10 Merck Sharp & Dohme 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
EP1299123A2 (en) * 2000-07-13 2003-04-09 Pharmacia Corporation Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
PE20021017A1 (es) 2001-04-03 2002-11-24 Pharmacia Corp Composicion parenteral reconstituible
AU2002303577B2 (en) * 2001-05-04 2006-06-08 Merck & Co., Inc. Method and compositions for treating migraines
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
JP4700916B2 (ja) * 2004-02-02 2011-06-15 富士フイルムファインケミカルズ株式会社 ピリジン誘導体の製造方法
US7271383B2 (en) * 2004-08-11 2007-09-18 Lexmark International, Inc. Scanning system with feedback for a MEMS oscillating scanner
EP2494992A1 (en) 2004-08-24 2012-09-05 Merck Sharp & Dohme Corp. Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events
CN101626787A (zh) * 2007-01-19 2010-01-13 马林克罗特公司 诊断的和治疗的环氧合酶-2结合配体
HUE028730T2 (en) 2009-02-27 2017-01-30 Cadila Healthcare Ltd Process for the preparation of etoricoxib
WO2011158250A1 (en) 2010-06-16 2011-12-22 Glenmark Generics Limited Process for preparation of 2, 3-diaryl-5-substituted pyridines and their intermediates
RU2591848C2 (ru) * 2010-11-15 2016-07-20 Вирдев Интермидиетс Пвт. Лтд. Способ получения селективного ингибитора циклооксигеназы-2
ITMI20110362A1 (it) * 2011-03-09 2012-09-10 F I S Fabbrica Italiana Sint P A Procedimento per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib.
WO2012163839A1 (en) 2011-05-27 2012-12-06 Farma Grs, D.O.O. A process for the preparation of polymorphic form i of etoricoxib
ITMI20111455A1 (it) 2011-07-29 2013-01-30 Italiana Sint Spa Nuovo procedimento per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib.
CN103204803A (zh) 2012-01-13 2013-07-17 阿尔弗雷德·E·蒂芬巴赫尔有限责任两合公司 用于合成依托考昔的方法
ITMI20120394A1 (it) 2012-03-14 2013-09-15 Zach System Spa Processo di sintesi di un chetosolfone derivato
EP2831045A2 (en) 2012-03-30 2015-02-04 Mylan Laboratories, Limited An improved process for the preparation of etoricoxib
GR1007973B (el) * 2012-06-26 2013-09-12 Φαρματεν Αβεε, Νεα ν-οξοιμινο παραγωγα ως ενδιαμεσα μιας βελτιωμενης μεθοδου παρασκευης 2,3-διαρυλο-5-υποκατεστημενων πυριδινων
HUE033525T2 (en) 2012-08-27 2017-12-28 Cadila Healthcare Ltd Pharmaceuticals containing Etoricoxib
ITVI20130014A1 (it) 2013-01-22 2014-07-23 Italiana Sint Spa Procedimento molto efficiente per preparare un intermedio di etoricoxib
WO2014114352A1 (en) * 2013-01-25 2014-07-31 Synthon Bv Process for making etoricoxib
CN104418799A (zh) * 2013-09-03 2015-03-18 天津药物研究院 一种依托考昔的晶型及其制备方法和应用
WO2015036550A1 (en) 2013-09-13 2015-03-19 Synthon B.V. Process for making etoricoxib
EP3268085A4 (en) 2015-03-13 2018-10-31 The Board of Trustees of The Leland Stanford Junior University Ltb4 inhibition to prevent and treat human lymphedema
CN104817473A (zh) * 2015-03-27 2015-08-05 南京大学 1-二甲氨基-3-二甲亚胺基-2-氯丙烯高氯酸盐在制备依托考昔中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA988522A (en) * 1972-05-05 1976-05-04 Haydn W.R. Williams 1,8-naphthyridine compounds
DE3842062A1 (de) * 1988-12-14 1990-06-28 Hoechst Ag Explosionssichere 1-dimethylamino-3-dimethylimino-2-arylpropen-1-salze, verfahren zu ihrer herstellung und ihre verwendung
SI0912518T1 (en) * 1996-07-18 2003-12-31 Merck Frosst Canada & Co. Substituted pyridines as selective cyclooxygenase-2 inhibitors
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors

Also Published As

Publication number Publication date
WO1999055830A2 (en) 1999-11-04
NZ507597A (en) 2004-02-27
BR9909844A (pt) 2001-04-03
SK15892000A3 (sk) 2001-07-10
AU759469B2 (en) 2003-04-17
EA200001102A1 (ru) 2001-04-23
CA2329193C (en) 2007-01-23
UA57143C2 (uk) 2003-06-16
ES2226378T3 (es) 2005-03-16
EA002975B1 (ru) 2002-12-26
EP1071745A2 (en) 2001-01-31
HK1031399A1 (en) 2001-06-15
CZ292515B6 (cs) 2003-10-15
DK1071745T3 (da) 2004-11-29
IL139127A0 (en) 2001-11-25
WO1999055830A3 (en) 1999-12-29
IL139127A (en) 2006-07-05
CA2329193A1 (en) 1999-11-04
EP1071745A4 (en) 2002-05-15
KR100414998B1 (ko) 2004-01-13
JP2002513035A (ja) 2002-05-08
BR9909844B1 (pt) 2010-10-19
HUP0101407A3 (en) 2002-12-28
PL193248B1 (pl) 2007-01-31
JP3834263B2 (ja) 2006-10-18
KR20010042941A (ko) 2001-05-25
EP1071745B1 (en) 2004-08-04
JP3325264B2 (ja) 2002-09-17
AR015279A1 (es) 2001-04-18
CN1306425A (zh) 2001-08-01
CZ20003940A3 (en) 2001-06-13
RS49945B (sr) 2008-09-29
DE69919151T2 (de) 2005-07-28
PL344108A1 (en) 2001-09-24
SK284805B6 (sk) 2005-11-03
SI1071745T1 (en) 2004-10-31
HU227627B1 (en) 2011-10-28
ATE272613T1 (de) 2004-08-15
DE69919151D1 (de) 2004-09-09
YU64100A (sh) 2002-11-15
JP2003040852A (ja) 2003-02-13
PT1071745E (pt) 2004-11-30
HRP20000722A2 (en) 2001-06-30
HUP0101407A2 (hu) 2001-09-28
AU3655799A (en) 1999-11-16
HRP20000722B1 (hr) 2009-07-31
TW474934B (en) 2002-02-01
US6040319A (en) 2000-03-21
BRPI9917739B1 (pt) 2016-05-03
US6252116B1 (en) 2001-06-26
CN1178658C (zh) 2004-12-08

Similar Documents

Publication Publication Date Title
BR9812837A (pt) Processo para fazer um composto, e, composto
BR9909844A (pt) Processo para sintetizar um composto, e, composto.
CY1107927T1 (el) Ενωσεις φωσφονικου
ES2115237T3 (es) Fenil heterociclos como inhibidores de la ciclooxigenasa-2.
ES2171723T3 (es) 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
BR9808923A (pt) Composto, e, processo para fazer o mesmo
BR0013311A (pt) Derivados substituìdos de 1,5-dihidropirrol-2-ona eficazes como antagonistas de receptores nmda para o tratamento de estados de dor
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
PT902022E (pt) Novos derivados de benzofuranona e processo para a sua producao
NZ228065A (en) 1,2,4-triazinediones and parasiticidal compositions; processes for preparation
BRPI0406824A (pt) Indolonaoxazoldinonas antiibacterianas, intermediários para seu preparo e composições farmacêuticas que as contêm
NO20016151L (no) Fremstilling av substituerte piperidin-4-oner
BR0013313A (pt) Derivados substituìdos de pirrolidino-2,3,4- triona-3-oxina eficazes como antagonistas de receptores de nmda
NO983511D0 (no) Difenylstilbener som pro-legemidler for COX-2-inhibitorer
PT1206452E (pt) Processo de preparacao de compostos benzoper-hidroisoindole
BR9909260A (pt) Processo para o preparo de (r)-alfa-(2,3-dimetóxifenil)-1-[2-(4-fluoro-fenil)etil]-4-pi peridinametanol
BR9610175A (pt) Composto processo de preparação do composto composição farmacêutica e utilização do composto
PT1280812E (pt) Ciclipostinas, processo para a sua preparacao e sua utilizacao
YU53998A (en) Process for making phenyl heterocycles useful as cox-2 inhibitors
PT1250335E (pt) Processo e intermediarios para a preparacao de imidazopiridinas
DE60114608D1 (de) Verfahren zur herstellung von anthracyclinederivaten
BR0315508A (pt) Processo para preparação de compostos de pirazol
BR0011559A (pt) Processo para a preparação de derivados de 10, 11-metano benzossuberano
BR0000184A (pt) Processo para a preparação de compostos heterocìclicos
PT1234817E (pt) Processo para a preparacao de midodrina

Legal Events

Date Code Title Description
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 24 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

Free format text: NOME ALTERADO DE: MERCK AND CO., INC.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25A Requested transfer of rights approved

Owner name: SCHERING CORPORATION (US)

B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/05/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/04/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 20/04/2019

B25B Requested transfer of rights rejected

Free format text: INDEFERIDO O PEDIDO DE TRANSFERENCIA CONTIDO NA PETICAO 870210062437 DE 09/07/2021DEVIDO AO DESPACHO PUBLICADO NA RPI 2630 DE 01/06/2021.